Tiwari Prachi, Katiyar Harshita, Rai Praveer, Goel Amit
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):669-671. doi: 10.1016/j.jceh.2021.06.023. Epub 2021 Jul 3.
In India, hepatitis C virus (HCV) infection is treated with sofosbuvir in combination with NS5A inhibitor (Daclatasvir, Ledipasvir, or Velpatasvir). A small proportion of them fail to achieve sustained virological response at 12 weeks (SVR12) and need retreatment. Triple-drug combination (Sofosbuvir/Velpatasvir/Voxilaprevir) is one of the options for retreatment. Here we describe a patient with cirrhosis and genotype 3a infection who was successfully treated with a triple-drug combination after relapse with two courses of Sofosbuvir-containing regimens.
在印度，丙型肝炎病毒（HCV）感染采用索磷布韦联合NS5A抑制剂（达卡他韦、来迪派韦或维帕他韦）进行治疗。其中一小部分患者在12周时未能实现持续病毒学应答（SVR12），需要重新治疗。三联药物组合（索磷布韦/维帕他韦/伏西瑞韦）是重新治疗的选择之一。在此，我们描述了一名患有肝硬化且感染基因3a型的患者，该患者在含索磷布韦方案的两个疗程复发后，采用三联药物组合成功治愈。
